Home Online Advertising With Pharma’s Ability To Target Limited, Precision Health Prescribes Regimen Of Context And Geography

With Pharma’s Ability To Target Limited, Precision Health Prescribes Regimen Of Context And Geography

SHARE:

Precision Health Media is one of a large number of ad tech companies that began life as a vertical ad network and have been trying to evolve into a broader “platform.” The New York-based company still has many of the attributes of an ad network — it was initially known as Good Health Media when it was launched four years ago with ad serving powered by Adify — such as representing 280 health sites.

As the company looks to build out some self-serve ad functions next year, the concentration right now involves sharpening its focus as a contextual/semantic provider, promising to match advertisers and agencies with sites that have shown they can directly reach allergy sufferers or those afflicted by, or deeply interested in, specific diseases like diabetes or multiple sclerosis.

“If a brand just wanted to reach those consumers looking into type-1 diabetics, we could find that kind of content by going through the 280 sites in our system,” says Bill Jennings, Precision Health’s CEO, in an interview with AdExchanger. “But we don’t just rely on semantics. For example, with diabetes, there happens to be an obvious belt of six or seven states with a higher than average incidence of the disease, so we’ll test inventory heavily against site readers in those areas. With pollen count, it’s the same thing, as we’ll target placements to readers in locations where allergy issues are trending.”

For the most part, behavioral targeting is off-limits to pharmaceutical marketers, Jennings notes. On average, Precision Health claims that its ConditionMatch contextual ad product delivers a click-through rate 40 percent higher than the industry average. It also claims that tests by a “major pharmaceutical marketer” — it wouldn’t identify the company — showed that ConditionMatch lowered cost-per-visit by 71 percent. Furthermore, Jennings points to ConditionMatch’s use of four years worth of site data, which allows the company to track the historical performance of a particular URL when it runs a specific kind of ad.

“The Interactive Advertising Bureau and other groups have agreed that drug companies should be tracking consumers’ illnesses or medical problems directly. It makes sense. And from a practical standpoint, it forces advertisers to do better forms of targeting to get to the right audience. For example, our advertisers are up to 50 percent more likely to reach a consumer who has filled a prescription when compared to targeting general health portals, such as WebMD.”

One of the biggest problems agencies with niche health conditions have is finding enough inventory. Again, because of the limited behavioral targeting options, audience buying is hindered to some extent. “If you think about conditions like gout, COPD, or MS, they might have to contact 12 to 18 sites individually to find the inventory. So we’re positioning ConditionMatch as a way to aggregate our sites’ collective 57 million monthly users and become a one-stop shop for media buyers.”

Must Read

How AudienceMix Is Mixing Up The Data Sales Business

AudienceMix, a new curation startup, aims to make it more cost effective to mix and match different audience segments using only the data brands need to execute their campaigns.

Broadsign Acquires Place Exchange As The DOOH Category Hits Its Stride

On Tuesday, digital out-of-home (DOOH) ad tech startup Place Exchange was acquired by Broadsign, another out-of-home SSP.

Meta’s Ad Platform Is Going Haywire In Time For The Holidays (Again)

For the uninitiated, “Glitchmas” is our name for what’s become an annual tradition when, from between roughly late October through November, Meta’s ad platform just seems to go bonkers.

Privacy! Commerce! Connected TV! Read all about it. Subscribe to AdExchanger Newsletters
Monopoly Man looks on at the DOJ vs. Google ad tech antitrust trial (comic).

Closing Arguments Are Done In The US v. Google Ad Tech Case

The publisher-focused DOJ v. Google ad tech antitrust trial is finished. A judge will now decide the fate of Google’s sell-side ad tech business.

Wall Street Wants To Know What The Programmatic Drama Is About

Competitive tensions and ad tech drama have flared all year. And this drama has rippled out into the investor circle, as evident from a slew of recent ad tech company earnings reports.

Comic: Always Be Paddling

Omnicom Allegedly Pivoted A Chunk Of Its Q3 Spend From The Trade Desk To Amazon

Two sources at ad tech platforms that observe programmatic bidding patterns said they’ve seen Omnicom agencies shifting spend from The Trade Desk to Amazon DSP in Q3. The Trade Desk denies any such shift.